

# Rachel E Rau

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9142524/publications.pdf>

Version: 2024-02-01

80  
papers

1,817  
citations

394421

19  
h-index

276875

41  
g-index

84  
all docs

84  
docs citations

84  
times ranked

3450  
citing authors

| #  | ARTICLE  | IF  | CITATIONS |
|----|--|-----|-----------|
| 1  | Perturbed hematopoiesis in individuals with germline DNMT3A overgrowth Tatton-Brown-Rahman syndrome. <i>Haematologica</i> , 2022, 107, 887-898.  | 3.5 | 15        |
| 2  | Targeting signaling pathways vulnerabilities for the treatment of IKZF1-deleted ph-negative B lymphoblastic leukemia.. <i>Journal of Clinical Oncology</i> , 2022, 40, 7033-7033.  | 1.6 | 1         |
| 3  | Effects of age, obesity, and body surface area on asparaginase-associated toxicities during acute lymphoblastic leukemia induction therapy: A report from the Children's Oncology Group.. <i>Journal of Clinical Oncology</i> , 2022, 40, 7000-7000.                                       | 1.6 | 0         |
| 4  | Efficacy and safety of intramuscular (IM) recombinant <i>Erwinia</i> asparaginase in acute lymphoblastic leukemia (ALL) or lymphoblastic lymphoma (LBL): The Children's Oncology Group (COG) AALL1931 study.. <i>Journal of Clinical Oncology</i> , 2022, 40, 7001-7001.                   | 1.6 | 1         |
| 5  | An Mb1-Cre-driven oncogenic Kras mutation results in a mouse model of T-acute lymphoblastic leukemia/lymphoma with short latency and high penetrance. <i>Leukemia</i> , 2021, 35, 1777-1781.   | 7.2 | 3         |
| 6  | Prognostic impact of minimal residual disease at the end of consolidation in NCI standard-risk B-lymphoblastic leukemia: A report from the Children's Oncology Group. <i>Pediatric Blood and Cancer</i> , 2021, 68, e28929.  | 1.5 | 9         |
| 7  | Can recombinant technology address asparaginase <i>Erwinia chrysanthemi</i> shortages?. <i>Pediatric Blood and Cancer</i> , 2021, 68, e29169.  | 1.5 | 18        |
| 8  | Optimal Timing of Blinatumomab for the Treatment of B-Lymphoblastic Leukemia. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2021, 21, S99-S101.   | 0.4 | 0         |
| 9  | Modeling <i>IKZF1</i> lesions in B-ALL reveals distinct chemosensitivity patterns and potential therapeutic vulnerabilities. <i>Blood Advances</i> , 2021, 5, 3876-3890.   | 5.2 | 6         |
| 10 | Association of race and ethnicity with clinical phenotype, genetics, and survival in pediatric acute myeloid leukemia. <i>Blood Advances</i> , 2021, 5, 4992-5001.   | 5.2 | 6         |
| 11 | A viral cause of APL. <i>Blood</i> , 2021, 138, 1653-1655.   | 1.4 | 3         |
| 12 | Initial Results from a Phase 2/3 Study of Recombinant <i>Erwinia</i> Asparaginase (JZP458) in Patients with Acute Lymphoblastic Leukemia (ALL)/Lymphoblastic Lymphoma (LBL) Who Are Allergic/Hypersensitive to <i>E. coli</i> -Derived Asparaginases. <i>Blood</i> , 2021, 138, 2307-2307. | 1.4 | 4         |
| 13 | Blinatumomab Associated Seizure Risk in Patients with Down Syndrome and B-Lymphoblastic Leukemia: An Interim Report from Children's Oncology Group (COG) Study AALL1731. <i>Blood</i> , 2021, 138, 2304-2304.  | 1.4 | 10        |
| 14 | Incidence and predictors of treatment-related conjugated hyperbilirubinemia during early treatment phases for children with acute lymphoblastic leukemia. <i>Pediatric Blood and Cancer</i> , 2020, 67, e28063.  | 1.5 | 9         |
| 15 | Phase 1/2 trial of talazoparib in combination with temozolomide in children and adolescents with refractory/recurrent solid tumors including Ewing sarcoma: A Children's Oncology Group Phase 1 Consortium study (ADVL1411). <i>Pediatric Blood and Cancer</i> , 2020, 67, e28073.         | 1.5 | 52        |
| 16 | Use of Allopurinol to Mitigate 6-Mercaptopurine Associated Gastrointestinal Toxicity in Acute Lymphoblastic Leukemia. <i>Frontiers in Oncology</i> , 2020, 10, 1129.   | 2.8 | 13        |
| 17 | How the COG is Approaching the High-Risk Patient with ALL: Incorporation of Immunotherapy into Frontline Treatment. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2020, 20, S8-S11.   | 0.4 | 3         |
| 18 | SIRPassing other xenograft murine models?. <i>Blood</i> , 2020, 135, 1612-1614.  | 1.4 | 0         |

| #  | ARTICLE   | IF   | CITATIONS |
|----|---|------|-----------|
| 19 | Experience with ponatinib in paediatric patients with leukaemia. British Journal of Haematology, 2020, 189, 363-368.  | 2.5  | 21        |
| 20 | The genomics of acute myeloid leukemia in children. Cancer and Metastasis Reviews, 2020, 39, 189-209.   | 5.9  | 26        |
| 21 | Cutting to the Front of the Line: Immunotherapy for Childhood Acute Lymphoblastic Leukemia. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2020, 40, e132-e143.   | 3.8  | 15        |
| 22 | A phase II/III study of JZP-458 in patients with acute lymphoblastic leukemia (ALL)/lymphoblastic lymphoma (LBL) who are hypersensitive to E. coli-derived asparaginases.. Journal of Clinical Oncology, 2020, 38, TPS7568-TPS7568.   | 1.6  | 4         |
| 23 | Effects of Race and Ethnicity on Clinical Features, Tumor Genetics and Outcome in Children with <i>KMT2A</i> Rearranged Acute Myeloid Leukemia. Blood, 2020, 136, 34-34.  | 1.4  | 0         |
| 24 | Impact of Race/Ethnicity on Pediatric Core Binding Factor AML Outcomes and Response to Gemtuzumab Ozogamicin. Blood, 2020, 136, 10-11.  | 1.4  | 0         |
| 25 | Prevention of mercaptopurine-induced hypoglycemia using allopurinol to reduce methylated thiopurine metabolites. Pediatric Blood and Cancer, 2019, 66, e27577.  | 1.5  | 11        |
| 26 | Sustained remission with azacitidine monotherapy and an aberrant precursor B-lymphoblast population in juvenile myelomonocytic leukemia. Pediatric Blood and Cancer, 2019, 66, e27905.  | 1.5  | 7         |
| 27 | 3488 A comparison between the Rolling 6 and 3+3 dose escalation study designs for phase 1 clinical trials. Journal of Clinical and Translational Science, 2019, 3, 30-31.   | 0.6  | 0         |
| 28 | Ponatinib use in two pediatric patients with relapsed Ph+ ALL with ABL1 kinase domain mutations. Pediatric Hematology and Oncology, 2019, 36, 514-519.  | 0.8  | 2         |
| 29 | A KLF4-DYRK2-mediated pathway regulating self-renewal in CML stem cells. Blood, 2019, 134, 1960-1972.   | 1.4  | 38        |
| 30 | Measure Twice, Cut Once: Therapeutic Editing of HSPCs Requires Precise Planning. Cell Stem Cell, 2019, 24, 511-512.   | 11.1 | 0         |
| 31 | Targeting Activated Signaling Pathways for the Treatment of IKZF1-Deleted B Lymphoblastic Leukemia. Blood, 2019, 134, 3789-3789.  | 1.4  | 2         |
| 32 | A Novel Short Latency, High Penetrance Model of KRAS Mutation-Driven T-Cell Acute Lymphoblastic Leukemia. Blood, 2019, 134, 3792-3792.  | 1.4  | 0         |
| 33 | Open-Label, Multicenter, Phase 2/3 Study of Recombinant Crisantaspase Produced in Pseudomonas Fluorescens (RC-P) in Patients with Acute Lymphoblastic Leukemia (ALL) or Lymphoblastic Lymphoma (LBL) Following Hypersensitivity to Escherichia coli-Derived Asparaginases. Blood, 2019, 134, 2586-2586. | 1.4  | 0         |
| 34 | Outcome of pediatric patients with acute lymphoblastic leukemia/lymphoblastic lymphoma with hypersensitivity to pegaspargase treated with PEGylated <i>Erwinia</i> asparaginase, pegcrisantaspase: A report from the Children's Oncology Group. Pediatric Blood and Cancer, 2018, 65, e26873.           | 1.5  | 48        |
| 35 | Maternal folate genes and aberrant DNA hypermethylation in pediatric acute lymphoblastic leukemia. PLoS ONE, 2018, 13, e0197408.  | 2.5  | 4         |
| 36 | A phase 1 study of eribulin mesylate (E7389), a novel microtubule-targeting chemotherapeutic agent, in children with refractory or recurrent solid tumors: A Children's Oncology Group Phase 1 Consortium study (ADVL1314). Pediatric Blood and Cancer, 2018, 65, e27066.                               | 1.5  | 15        |

| #  | ARTICLE   | IF   | CITATIONS |
|----|---|------|-----------|
| 37 | Using genomics to define pediatric blood cancers and inform practice. Hematology American Society of Hematology Education Program, 2018, 2018, 286-300.   | 2.5  | 6         |
| 38 | Precise Modeling of IKZF1 Alterations in Human B-Cell Acute Lymphoblastic Leukemia Cell Lines Reveals Distinct Chemosensitivity, Homing, and Engraftment Properties. Blood, 2018, 132, 549-549.   | 1.4  | 1         |
| 39 | Phase I Study of the Selinexor in Relapsed/Refractory Childhood Acute Leukemia. Blood, 2018, 132, 1405-1405.  | 1.4  | 5         |
| 40 | Knock-in of the Wt1 R394W mutation causes MDS and cooperates with Flt3/ITD to drive aggressive myeloid neoplasms in mice. Oncotarget, 2018, 9, 35313-35326.   | 1.8  | 6         |
| 41 | Abstract 145: Pharmacologic inhibition of SIAH2 stabilizes DYRK2 and inhibits survival and self-renewal in chronic myeloid leukemia (CML) leukemic stem cells. , 2018, , .  |      | 0         |
| 42 | Mosaic DNMT3A Germline Mutation As a Model for Mutant DNMT3A Competitive Advantage in the Blood Lineage. Blood, 2018, 132, 173-173.   | 1.4  | 0         |
| 43 | Ethnic disparities relative to disease features and outcomes in children with acute myeloid leukemia. Pediatric Blood and Cancer, 2017, 64, e26487.   | 1.5  | 10        |
| 44 | 50 Years Ago in The Journal of Pediatrics. Journal of Pediatrics, 2017, 183, 140.   | 1.8  | 0         |
| 45 | CMML/JMML PDXs: as easy as 1, 2, NSG-SGM3. Blood, 2017, 130, 385-386.   | 1.4  | 3         |
| 46 | Klinefelter syndrome and 47, <sc>XYY</sc> syndrome in children with B cell acute lymphoblastic leukaemia. British Journal of Haematology, 2017, 179, 843-846.   | 2.5  | 4         |
| 47 | Mixed-phenotype acute leukemia (MPAL) exhibits frequent mutations in DNMT3A and activated signaling genes. Experimental Hematology, 2016, 44, 740-744.  | 0.4  | 48        |
| 48 | Beyond KIT in CBF-AML: chromatin and cohesin. Blood, 2016, 127, 2370-2371.  | 1.4  | 6         |
| 49 | DOT1L as a therapeutic target for the treatment of DNMT3A-mutant acute myeloid leukemia. Blood, 2016, 128, 971-981.   | 1.4  | 107       |
| 50 | DNMT3A Loss Drives Enhancer Hypomethylation in FLT3-ITD-Associated Leukemias. Cancer Cell, 2016, 29, 922-934.   | 16.8 | 107       |
| 51 | A phase 1 study of eribulin mesylate (E7389), a novel microtubule targeting chemotherapeutic agent in children with refractory or recurrent solid tumors (excluding CNS), including lymphomas: a Children's Oncology Group Phase 1 Consortium study (ADVL1314).. Journal of Clinical Oncology, 2016, 34, 2567-2567. | 1.6  | 1         |
| 52 | Aberrant Precursor B Lymphoid Blast Population in a Patient with Juvenile Myelomonocytic Leukemia. Blood, 2016, 128, 5557-5557.   | 1.4  | 0         |
| 53 | Leukemia Fusion Gene Detection in the Clinical Molecular Laboratory Using RNA-Based Targeted Next-Generation Sequencing. Blood, 2016, 128, 4074-4074.   | 1.4  | 0         |
| 54 | DNMT3A in haematological malignancies. Nature Reviews Cancer, 2015, 15, 152-165.  | 28.4 | 379       |

| #  | ARTICLE   | IF  | CITATIONS |
|----|---|-----|-----------|
| 55 | Poorer Relapse-Free Survival in Hispanic Children Diagnosed with Acute Myeloid Leukemia Compared with Non-Hispanics: A Texas Single Institution Experience. <i>Blood</i> , 2015, 126, 1312-1312.  | 1.4 | 2         |
| 56 | Targeting BCL6-Mediated Resistance to BCR-ABL Targeted Tyrosine Kinase Inhibitors (TKIs) in Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia (Ph+ ALL) through the Addition of Histone Deacetylase (HDAC) Inhibitors. <i>Blood</i> , 2015, 126, 1277-1277. | 1.4 | 0         |
| 57 | A Wilms Tumor 1 (WT1) Mutation Causes Myelodysplastic Syndrome in a Knock-in Mouse Model, and a Mixed Myelodysplastic/Myeloproliferative Neoplasm in Double Knock-in Mice with WT1 and FLT3/ITD Mutations. <i>Blood</i> , 2015, 126, 312-312.                           | 1.4 | 1         |
| 58 | NPMc+ cooperates with Flt3/ITD mutations to cause acute leukemia recapitulating human disease. <i>Experimental Hematology</i> , 2014, 42, 101-113.e5.   | 0.4 | 32        |
| 59 | Plerixafor as a chemosensitizing agent in pediatric acute lymphoblastic leukemia: efficacy and potential mechanisms of resistance to CXCR4 inhibition. <i>Oncotarget</i> , 2014, 5, 8947-8958.  | 1.8 | 51        |
| 60 | DOT1L As a Therapeutic Target for the Treatment of DNMT3A-Mutant Acute Myeloid Leukemia. <i>Blood</i> , 2014, 124, 614-614.   | 1.4 | 0         |
| 61 | Leukemogenic Wilms Tumor 1 (WT1) Mutations Enhance Progenitor Self Renewal, Inhibit Terminal Myeloid Differentiation, and Influence Survival in a Mouse Model. <i>Blood</i> , 2014, 124, 3572-3572.   | 1.4 | 12        |
| 62 | Next-Generation NAMPT Inhibitors Identified by Sequential High-Throughput Phenotypic Chemical and Functional Genomic Screens. <i>Chemistry and Biology</i> , 2013, 20, 1352-1363.   | 6.0 | 72        |
| 63 | MLL rearranged acute lymphoblastic leukaemia stem cell interactions with bone marrow stroma promote survival and therapeutic resistance that can be overcome with CXCR4 antagonism. <i>British Journal of Haematology</i> , 2013, 160, 785-797.                         | 2.5 | 39        |
| 64 | Dnmt3a-Deletion Accelerates FLT3-ITD Malignancies In Mice By Hypomethylation Of Enhancer Sites and Activating Stem Cell Programs; Implications For Therapy. <i>Blood</i> , 2013, 122, 595-595.  | 1.4 | 1         |
| 65 | Next-Generation NAMPT Inhibitors For ALL Identified By Sequential High-Throughput Phenotypic Chemical and Functional Genomic Screens. <i>Blood</i> , 2013, 122, 171-171.  | 1.4 | 0         |
| 66 | Oncogenic Wilms Tumor 1 (WT1) Mutation Augments Hematopoietic Progenitor Cell Clonogenicity and Promotes Expansion Of The Long-Term Hematopoietic Stem Cell (LT-HSC) Compartment: Implications For WT1-Mediated Leukemogenesis. <i>Blood</i> , 2013, 122, 1269-1269.    | 1.4 | 0         |
| 67 | Chemotherapy-Induced CXCR4 Modulation Predicts the In Vivo Efficacy of Plerixafor As a Chemosensitizer in Acute Leukemia. <i>Blood</i> , 2011, 118, 1410-1410.  | 1.4 | 0         |
| 68 | Leukemogenic WT1 Mutations Increase Proliferation by Accelerating Cell Entry Into S-Phase, and Synergize with FLT3/ITD Mutations to Enhance These Aberrant Cell Cycle Effects. <i>Blood</i> , 2011, 118, 2437-2437.   | 1.4 | 0         |
| 69 | Fatal Infection Caused by <i>Cupriavidus gilardii</i> in a Child with Aplastic Anemia. <i>Journal of Clinical Microbiology</i> , 2010, 48, 1005-1007.   | 3.9 | 39        |
| 70 | Cytoplasmic Nucleophosmin (NPMc+) Mutations and FMS-Like Tyrosine Kinase 3 (Flt3) Internal Tandem Duplication (ITD) Mutations Cooperate to Cause Leukemia In a Mouse Model. <i>Blood</i> , 2010, 116, 145-145.  | 1.4 | 1         |
| 71 | Nucleophosmin (NPM1) mutations in adult and childhood acute myeloid leukaemia: towards definition of a new leukaemia entity. <i>Hematological Oncology</i> , 2009, 27, 171-181.   | 1.7 | 127       |
| 72 | Combinations of the Histone Deacetylase Inhibitor Entinostat (SNDX-275, MS-275) and Imatinib Have Divergent Effects in Imatinib-Sensitive Vs. Imatinib-Resistant p210-BCR/ABL Expressing Cell Lines.. <i>Blood</i> , 2009, 114, 2742-2742.                              | 1.4 | 0         |

| #  | ARTICLE  | IF  | CITATIONS |
|----|--|-----|-----------|
| 73 | Triad of Severe Abdominal Pain, Inappropriate Antidiuretic Hormone Secretion, and Disseminated Varicella-Zoster Virus Infection Preceding Cutaneous Manifestations After Hematopoietic Stem Cell Transplantation. <i>Pediatric Infectious Disease Journal</i> , 2008, 27, 265-268. | 2.0 | 37        |
| 74 | The incidence and clinical significance of nucleophosmin mutations in childhood AML. <i>Blood</i> , 2007, 110, 979-985.  | 1.4 | 193       |
| 75 | Incidence and Clinical Significance of Nucleophosmin Mutations in Childhood AML: A Childrens Oncology Group Study.. <i>Blood</i> , 2006, 108, 221-221.   | 1.4 | 1         |
| 76 | Predictors of Acute Intracranial Pathology Identified by Computerized Tomography in Children with Sickle Cell Disease.. <i>Blood</i> , 2006, 108, 3798-3798.   | 1.4 | 0         |
| 77 | Enteric gram-negative bacilli bloodstream infections: 17 years' experience in a neonatal intensive care unit. <i>American Journal of Infection Control</i> , 2004, 32, 189-195.  | 2.3 | 98        |
| 78 | Constitutive loss of DNMT3A causes morbid obesity through misregulation of adipogenesis. <i>ELife</i> , 0, 11, .   | 6.0 | 12        |
| 79 | Murine Models of Acute Myeloid Leukemia. <i>Frontiers in Oncology</i> , 0, 12, .   | 2.8 | 4         |
| 80 | Current Use of Asparaginase in Acute Lymphoblastic Leukemia/Lymphoblastic Lymphoma. <i>Frontiers in Pediatrics</i> , 0, 10, .  | 1.9 | 22        |